Lung cancer is the leading cause of cancer death among men in both developed and less developed countries, and has surpassed breast cancer as the main cause of cancer death among women in developed countries Torre et al., 2015) . Estimates of European cancer mortality predicted that in 2015, the mortality rate from lung cancer in men would fall by 9% compared to 2009, while in women it would increase by 9%, making it the cancer with the highest mortality rate in women (Malvezzi et al., 2015) . In addition, lung cancer deaths in women in the UK are expected to quadruple over the next 30 years (Maddams, Utley, & Moller, 2012).
. The differences may be due to a number of factors including genetic, hormonal, and environmental influences and viral infection (Mazieres et al., 2013) .
Although many studies have investigated gender differences in lung cancer, the retrospective study led by the Spanish Lung Cancer Group showed significant differences in the characteristics of lung cancer between Spanish female and male patients with advanced non-small-cell lung cancer (NSCLC), revealing better clinical trial outcomes in women compared to men (Isla et al., 2006) .
The ICAPEM Group (Asociación para la Investigación del Cáncer de Pulmón en Mujeres) is a Spanish association led by medical oncologists specialised in lung cancer, which aims to expand the knowledge about lung cancer in women, to collaborate in lung cancer prevention, particularly in the battle against smoking, and to further investigate gender differences in lung cancer. In the light of the above, we aimed to conduct the WORLD07 project: a female-specific database to prospectively analyse the characteristics of Spanish women with lung cancer as a first step to raise awareness of lung cancer among the general population, healthcare system providers and politicians. The aim of this study is to characterise the clinical, histological, molecular and treatment-related features of lung cancer among Spanish women.
| PATIENTS AND ME THODS

| Study design and setting
We conducted a multicenter, prospective and female-specific epidemiological study. Data were collected from the patients' medical records and directly from patient interviews, and then recorded in an electronic database. The data collected included ethnicity, age at menarche, type and duration of hormone replacement therapy (HRT), oral contraceptive use, menopausal status, smoking history, risk factors, family history, previous history of cancer, lung cancer history and treatment and molecular markers.
The protection and confidentiality of the patients' data in the database were guaranteed. The study was approved by the Institutional Review Board at each hospital participating in the study, and conducted in accordance with the International Guidelines for Ethical Review of Epidemiological Studies and the Declaration of Helsinki. Written informed consent was obtained from all patients to use their data prior to inclusion. 
| Patient population
| Statistical considerations
Descriptive statistics were used to analyse the clinical, histological, molecular and treatment-related features. Overall survival (OS) was calculated using the Kaplan-Meier method and was defined as the time from pathological diagnosis of lung cancer to death or last recorded follow-up, which should match the last data entry for each patient, and the log-rank test was used to analyse differences in survival. Statistical significance was set up at p < 0.05 and all analyses were generated using the SPSS software (version 13.0; SPSS Inc., Chicago, IL, USA).
| RE SULTS
| Patient characteristics
A total of 2,068 women were recruited at 38 oncology-based centres across Spain. Of these, eight women were excluded from the analysis, and therefore 2,060 patients were analysed. Patient characteristics and demographics are shown in Table 1 . Briefly, the median age was 61.3 years and the vast majority were white (98.6%).
A third of women were either overweight (23.2%) or obese (11.0%), 53.7% of patients were married or living with a partner, and around 41.7% of women had basic education.
Most patients were postmenopausal (80.2%), but only a small proportion of patients were taking HRT (6.5%) and 23.9% were on oral contraceptives. Approximately two-thirds of women (65.9%) had children, most of them (49.5%) having at least two.
Regarding smoking history, non-smoker was the most common category (39.0%), along with smokers (43.4%), with a median smoking duration of 34.1 years, while occupational exposure only accounted for 2.3% of women (Table 2) .
A total of 876 (42.5%) women had a family history of cancer, with first-degree relatives for 467 (53.3%) women. Lung cancer was the most frequent malignancy in 304 (34.7%) women, followed by breast (25%) and colon (17.6%); and 247 (12.0%) women reported a previous history of cancer, with breast cancer being the most common type (Table 3) .
The clinical characteristics of the current lung cancer are shown in Table 4 . Most patients with small-cell lung cancer (SCLC) had extensive-stage disease (52.6%) and the most common type of NSCLC was adenocarcinoma (71.4). Among patients with stage IV NSCLC, 70.8% had received first-line chemotherapy. More details on patients' cancer-related treatment are presented in Table 5 .
| Survival
Median OS for the entire group of women with lung cancer was 
| D ISCUSS I ON
To the best of our knowledge, the WORLD07 is the first prospective study including a large number of female patients diagnosed with lung cancer who attended a medical oncology department at university hospitals in Spain over a period of 6 years.
The results of this prospective analysis showed that most women had NSCLC, with adenocarcinoma being the most common type. The incidence of SCLC (13.8%) was similar to the incidence reported in the US (13%) (Govindan et al., 2006) and in South East England (11%) (Riaz et al., 2012) . Nonetheless, the occurrence of SCLC is globally decreasing, possibly reflecting the reduction in the prevalence of cigarette smoking and changes in the type of cigarettes smoked (Govindan et al., 2006) . showed that even though the overall risk of lung cancer was similar among women and men, female heavy smokers had a higher risk of lung cancer compared to men (Papadopoulos et al., 2014) . Similarly, Powell et al. showed that women who were moderate or heavy smokers had a higher risk of lung cancer compared to men (Powell, Iyen-Omofoman, Hubbard, Baldwin, & Tata, 2013) .
Although a similar proportion of patients were either smokers (43.4%) or non-smokers (39.0%), 38.4% of non-smokers were passive smokers, mostly at home. While the increase in lung cancer incidence and mortality in women is thought to be primarily due to the increasing prevalence of smoking, the incidence (Alberg et al., 2013) and risk (Kovalchik et al., 2013) of lung cancer among people who have never smoked are higher in women than in men. Compared to non-smoking men, non-smoking women appear to be at a two-tothree-times greater risk of developing lung cancer, suggesting that other factors, such as passive smoking or environmental exposure, play a key role.
There is conflicting evidence regarding the role of female hormones, particularly oestrogen, as a risk factor for the development and progression of lung cancer (Alberg et al., 2013; Schwartz et al., 2015) . While some studies have suggested that these may be risk factors (Alberg et al., 2013) association between reproductive history or HRT use and the risk of lung cancer (Schwartz et al., 2015) . Compared to men, women with NSCLC appeared to have a survival advantage (Nakamura et al., 2011) . In our series, most women were postmenopausal (80.2%), HRT was uncommon (6.5%), the median number of children was 1.9, and the mean age at which mothers had given birth to their first child was 26 years. In addition, just over half the women were married or living with a partner. Married patients, both men and women, have been shown to be less likely to present with metastatic disease and to die from their cancers and more likely to receive definitive therapy than unmarried patients (Aizer et al., 2013) .
Among women with a family history of cancer, lung cancer was the most common malignancy in over one third of these patients, while among those patients with a previous history of cancer, the most frequently reported malignancy was breast cancer, in almost 40% of patients, followed by cervical cancer (8.9%) and colon cancer (6.1%). In the WORLD07 study, 859 (41.7%) patients had completed basic education, which has been associated in previous studies with an increased risk of lung cancer (Montez & Zajacova, 2013; Sharpe, McMahon, Raab, Brewster, & Conway, 2014) . In a US study, a low educational level (0-11 years) was related with a higher mortality rate among non-Hispanic white women compared to women who had high school or college education. Furthermore, the mortality rate in women with basic education increased between 1986-1994 and 2003-2006 , while it decreased in better-educated women over the same time (Montez & Zajacova, 2013) . In a study in Scotland, the age-adjusted relative risk of lung cancer increased in both men and women who had no degrees (3.05 and 3.24, respectively) or a nondegree qualification (1.32 and 1.78, respectively) versus those with a degree (Sharpe et al., 2014) .
A third of women were either overweight (23.2%) or obese (11.0%) in the WORLD07 study. There is conflicting evidence as to whether weight is a risk factor for lung cancer. One US study at Staten Island University Hospital found that obesity is a potential risk factor for lung cancer (Gupta, Hassan, Bhatt, Abdul Sater, & Dilawari, 2014) , while another study in African American women concluded that a high body mass index was associated with a lower risk of lung cancer (Bethea et al., 2013) . A meta-analysis of 31 studies concluded that overweight and obesity are protective factors against lung cancer, particularly in current and former smokers (Yang et al., 2013 ). Obesity appears to have a protective effect for lung cancer survival, being associated with lower lung cancer mortality (Leung et al., 2011) .
Female sex is a favourable prognostic factor in lung cancer, which is independent of histology and stage. In studies conducted in Poland, Taiwan, and the US, the relative risk of death in men with lung cancer was 1.15, 1.18 and 1.20 respectively (Harichand-Herdt & Ramalingam, 2009) . Median OS for the Spanish women enrolled in WORLD07 was 24.0 months and the 2-year survival rate was 50.0%.
For patients with stage IV NSCLC, median OS was 16.3 months.
These survival rates confirm the survival advantage in women described in previous studies by our group (Isla et al., 2006; Remon et al., 2014) and in other studies (Harichand-Herdt & Ramalingam, 2009 ). In an analysis of four SCLC first-line trials, there was a statistically significant difference in the median OS in women compared to men (12.9 vs. 9.3 months; p < 0.001) (Isla et al., 2006) . Median time to progression (TTP) was also significantly longer in women than men (6.8 vs. 5.3 months; p < 0.009) (Isla et al., 2006) . A multivariate analysis showed that female sex was an independent predictor for both OS (hazard ratio [HR] 1.5, 95% CI 1.2-1.9; p < 0.0001) and TTP (HR 1.4, 95% CI 1.1-1.7; p < 0.001) (Isla et al., 2006) .
In addition to the obvious limitations arising from a prospective epidemiological study with a number of missing or unknown data, the authors acknowledge that the actual study comprised exclusively a female cohort of patients with lung cancer, limiting therefore the interpretation of the results in terms of gender comparison.
In conclusion, lung cancer in women is becoming a major public health issue in many countries. Clearly, there have been large and persistent increases in the risk of lung cancer among female cigarette smokers; however, other factors need to be considered to explain the differences in susceptibility and lung cancer outcomes.
By analysing distinctive features through studies such as WORLD07, we hope to promote specific areas of research and influence local healthcare policies. Nevertheless, more comprehensive strategies for prevention, diagnosis and treatment are still needed for both men and women, considering that a more innovative research approach is probably warranted for genetic susceptibility and lung cancer in patients who have never smoked.
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